Ultra-Committed
- - - To transform the lives of as many people living with rare diseases as possible, we dedicate ourselves every day to the development and delivery of treatments of rare diseases where none currently exist.
  - - Ultra-Committed
      Learn more
  - Ultra-committed
Research
- - - We develop therapies for rare and ultrarare genetic diseases by exploring an array of drug modalities to select the best treatment strategy for each genetic disease we are studying.
  - - Research
      Learn more
Medicines
Partnerships
Join Our Team
- - - We have built a talented team and a vibrant, people-first culture. We share a passion for helping those living with rare diseases.
  - - Join our team
      Learn More
  - Join Our Team
Newsroom
- - - Access news releases, presentations, and blog posts to follow the latest developments at Ultragenyx.
  - - Newsroom
      Learn More
  - Newsroom
Investors
- - Investor Relations

Events
& presentations

Corp presentation

Corporate Presentation

Top-Line Phase 3 Results DTX401 for Glycogen Storage Disease Type Ia (GSDIa)

GTX-102 for Angelman Syndrome Phase 1/2 Interim Data Update

GTX-102 for Angelman Syndrome Phase 1/2 Interim Data Update

Corporate Responsibility

Ultragenyx 2023 Corporate Responsibility Report

Ultragenyx 2023 Analyst Day

Sep 18, 2024 3:05 PM BST

Bank of America Global Healthcare Conference

Sep 17, 2024 1:20 PM EDT

Cantor Global Healthcare Conference